Loading...

CEL-SCI Corporation

CVMAMEX
Healthcare
Biotechnology
$3.20
$-0.11(-3.32%)
U.S. Market opens in 42h 20m

CEL-SCI Corporation Fundamental Analysis

CEL-SCI Corporation (CVM) shows weak financial fundamentals with a PE ratio of -1.07, profit margin of 0.00%, and ROE of -2.26%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position24.55%
PEG Ratio-0.01

Areas of Concern

ROE-2.26%
Operating Margin0.00%
We analyze CVM's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -211.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-211.9/100

We analyze CVM's fundamental strength across five key dimensions:

Efficiency Score

Weak

CVM struggles to generate sufficient returns from assets.

ROA > 10%
-1.04%

Valuation Score

Excellent

CVM trades at attractive valuation levels.

PE < 25
-1.07
PEG Ratio < 2
-0.01

Growth Score

Moderate

CVM shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
53.56%

Financial Health Score

Excellent

CVM maintains a strong and stable balance sheet.

Debt/Equity < 1
0.95
Current Ratio > 1
1.39

Profitability Score

Weak

CVM struggles to sustain strong margins.

ROE > 15%
-226.10%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is CVM Expensive or Cheap?

P/E Ratio

CVM trades at -1.07 times earnings. This suggests potential undervaluation.

-1.07

PEG Ratio

When adjusting for growth, CVM's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values CEL-SCI Corporation at 2.29 times its book value. This may indicate undervaluation.

2.29

EV/EBITDA

Enterprise value stands at -0.90 times EBITDA. This is generally considered low.

-0.90

How Well Does CVM Make Money?

Net Profit Margin

For every $100 in sales, CEL-SCI Corporation keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-2.26 in profit for every $100 of shareholder equity.

-2.26%

ROA

CEL-SCI Corporation generates $-1.04 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.04%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-2.12 in free cash annually.

$-2.12

FCF Yield

CVM converts -77.71% of its market value into free cash.

-77.71%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.07

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.29

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.95

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.39

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.26

vs 25 benchmark

ROA

Return on assets percentage

-1.04

vs 25 benchmark

ROCE

Return on capital employed

-1.30

vs 25 benchmark

How CVM Stacks Against Its Sector Peers

MetricCVM ValueSector AveragePerformance
P/E Ratio-1.0728.81 Better (Cheaper)
ROE-226.10%643.00% Weak
Net Margin0.00%-44312.00% (disorted) Weak
Debt/Equity0.950.36 Weak (High Leverage)
Current Ratio1.394.50 Neutral
ROA-103.99%-17799.00% (disorted) Weak

CVM outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews CEL-SCI Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-100.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

76.18%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

-33757.32%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ